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Background: Matrix metalloproteinases (MMPs) are pleiotropic enzymes involved in
extracellular protein degradation and turnover. MMPs are implicated in the pathogenesis
of many neurological diseases, including multiple sclerosis (MS).
Objective: To search the level of MMPs in the cerebrospinal fluid (CSF) of MS patients
and detect possible disease-specific patterns.
Methods: CSF samples from 32MS patients and, from 15 control subjects with other
inflammatory neurological diseases (OIND) were analyzed. The Bio-Plex Pro HumanMMP
9-Plex Panel (Bio-Rad) was used for the quantification of MMP-1, MMP-2, MMP-3,
MMP-7, MMP-8, MMP-9, MMP-10, MMP-12, and MMP-13.
Results: CSFMMP-1 andMMP-12 levels were significantly reduced in MS as compared
with OIND. In MS patients’ CSF: (i) MMP-1 levels were significantly higher in women
vs. men; (ii) MMP-10 concentrations were higher in patients with CSF-restricted IgG
oligoclonal bands, and (iii) MMP-7 levels were increased in patients with longer disease
duration. In the OIND group MMP-7 and MMP-12 levels significantly and directly
correlated with age.
Conclusions: Our study contributes to investigating the role of MMPs in MS, with regard
to CSF immunological features and disease duration. Sex-specific differences were also
detected in MMPs CSF levels.
Keywords: multiple sclerosis, cerebrospinal fluid, matrix metalloproteinases, sex, aging, blood-brain-barrier,
neuroinflammation, neurodegeneration
INTRODUCTION
In multiple sclerosis (MS) the migration of immunocompetent cells into the central nervous system
(CNS) requires the opening of the blood-brain barrier (BBB) (1), a mechanism in which proteins
degradation represents a crucial step (2). Matrix metalloproteinases (MMPs) are pleiotropic
calcium-requiring and zinc-containing proteolytic enzymes involved in extracellular matrix (ECM)
degradation and turnover (3). MMPs are members of the metzincins family, so named for the
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presence of a conserved Methionine residue at the active site
and for the use of a zinc ion in the enzymatic reaction
(4). Twenty-three enzymes, encoded by 24 genes, have been
identified in humans and included in this family (5). MMPs
comprise both secreted and membrane-associated enzymes, and
are classified into five subgroups according to their structure:
collagenases (MMP-1, MMP-8, and MMP-13), stromelysins
(MMP-3 and MMP-10), gelatinases (MMP-2 and MMP-9), a
more heterogeneous subgroup containing matrilysin (MMP-7),
enamelysin (MMP-20), macrophage metalloelastase (MMP-12),
and MMP-19, and membrane-type MMP (MT-MMP) (MT-
MMP-1-4 and stromelysin-3, MMP-11) (6). In the functional
development of the CNS MMPs play a fundamental role
in neurogenesis, axonal guidance, synaptic plasticity, learning
and memory (7), and have been reported in association with
ischemia/hypoxia, epilepsy, and seizure, Huntington’s disease,
vascular dementia, Parkinson’s disease, malignant gliomas (8).
Abnormal concentrations of MMPs have been reported in MS
and its animal models, and in different phases of disease course
and progression (7).
A distinctive pattern of MMPs expression in different cellular
populations was reported. MMP-11, MMP-26 and MMP-27 were
enriched in B cells, while MMP-15, MMP-16, MMP-24, and
MMP-28 were prominent in T lymphocytes. Of interest was
the enrichment of a majority of MMPs members in monocytes:
MMP-1, MMP-3, MMP-9, MMP-10, MMP-14, MMP-19, and
MMP-25 (9). Moreover, MMP-12 deficiency ameliorated a virus-
induced murine model of MS (10). Likely due to the larger
reagent availability, gelatinases (MMP-2 and MMP-9) represent
the most studied MMPs in MS. In particular, MMP-9 levels were
higher in relapsing remitting as compared to progressive MS (11)
and active MMP-2 and MMP-9 were reciprocally associated to
disease remission and activity, respectively (12, 13). In addition,
gelatinases were described altered in response to both first and
second line disease modifying therapies (interferon-beta 1a and
natalizumab, respectively) in MS patients (14, 15).
We aimed to search the level of nine MMPs in the
cerebrospinal fluid (CSF) of MS patients comparing it with a
population of controls and with multiplex assay, in the attempt
to ultimately investigate the role of MMPs in the disease.
METHODS
Study Design
This study retrospectively included 32 patients with relapsing-
remitting MS according to the currently accepted criteria (16).
At the time of sample collection (a) disease duration was defined
as the time (months) elapsed between clinical onset and study
time; (b) the presence of CSF-restricted IgG oligoclonal bands
(OCB) was recorded as intrathecal immunoglobulin synthesis;
(c) the number of T2-weighted lesions on magnetic resonance
imaging (MRI) scans was recorded. Patients affected by other
inflammatory neurological diseases (OIND) were selected as
controls. None of the study subjects underwent treatment with
immunosuppressants or immune-modulating drugs, including
steroids, at the time of sampling.
In MS group, lumbar puncture was performed as part of the
diagnostic work-up for a suspect of MS, subsequently all patient
were ‘naïve’ for disease modifying treatment.
The study was approved by the Committee for Medical Ethics
in Research of Ferrara and written consent to study participation
was obtained from all subjects.
Sample Handling
CSF samples were obtained fromMS andOIND patients through
diagnostic lumbar puncture. Cell-free CSF was obtained after
centrifugation at 3,000 rpm at 20◦C for 15min. Supernatants
were collected, under sterile conditions, in aliquots of 500 µl,
coded, frozen and stored at −80◦C until assay. As routine
CSF examination, intrathecal immunoglobulin synthesis was
investigated through isoelectric focusing followed by IgG-specific
immunoblotting in paired CSF and serum samples (17).
Magnetic Resonance Imaging Analysis
All MS patients underwent brain MRI scans on a 1.5-Tesla
MRI unit (GE Signa Horizon, General Electric Medical Systems,
Milwaukee, WI, USA) within 48 h after CSF sampling. Routinely
used T1-weighted axial spin echo images were obtained∼10min
after intravenous injection of 0.1 mmol/kg of Gadopentetic
acid (Gd-DTPA) in each patient. Lesions showing contrast-
enhancement on T1-weighted scans were defined as active
(Gd+). All neuroimaging data were independently reviewed
by two neuroradiologists (L.B. and E.F., with 15 and 20-years
experience, respectively) blinded to the patients’ clinical and
laboratory data. Discrepancies between readers were resolved by
consensus adjudication.
MMP Multiplex Assay
MMPs concentrations in CSF were determined in all samples
through the Pro
TM
HumanMMP 9-plex Assay (including: MMP-
1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-
12, and MMP-13), a multiplex suspension immunomagnetic
assays based on the use of fluorescently dyed magnetic beads
covalently conjugated withmonoclonal antibodies specific for the
target proteins (Bioplex, Bio\\Rad Labs, Hercules, CA, USA).
As indicated by the manufacturer, the lower detection limit
was 1.0 pg/mL, while the mean intra-assay variability was 10%.
Levels of all analytes were determined using a Bio-Plex 200 array
reader, based on Luminex X-Map Technology (Bio\\Rad Labs,
Hercules,CA, USA). The protein concentrations (expressed as
pg/mL) were calculated through a standard curve.
Statistical Analysis
Frequencies (percent) and chi-square statistics were reported
for categorical variables and mean [standard deviation (SD)]
and t-student statistics for continuous variables as descriptives.
The log-normal transformation was applied to non-normally
distributed data. Mann–WhitneyU-test was used to compareMS
vs. OIND patients and MS subgroups each other. Spearman’s
rank test was used for correlation. Analysis of covariance
(ANCOVA) with MMPs CSF levels as dependent variables, status
(MS vs. OIND) as fixed factor, and sex and age at study time
as covariates. Two-tail p-values were reported and statistical
Frontiers in Neurology | www.frontiersin.org 2 December 2018 | Volume 9 | Article 1080
Castellazzi et al. Matrix Metalloproteinases in Cerebrospinal Fluid
significance was set at p < 0.05. The Statistical Package for the
Social Sciences (SPSS R©) version 19 for Windows and OSX (SPSS
Inc., IBM R©, Somers, New York, USA) and Prism R© (GraphPad
Software Inc.) were used for statistical analysis.
RESULTS
The study was conducted on 47 individuals, 32 patients with
a diagnosis of MS, and 15 control subjects suffering from
OIND. The main clinical-demographic features of the study
population are reported in Table 1. The women:men ratio was
marginally higher in the MS than in the OIND group (3:1 vs.
0.9:1; p = 0.056), and mean age at study time was significantly
higher in the OIND than in the MS group (58.6 vs. 39.4 years,
p= 0.000004).
MMP CSF Levels in MS Patients and
Controls
The percentage of samples with detectable levels of each MMPs
was similar in MS and OIND (Table 2). MMP-3 resulted
TABLE 1 | Clinical and demographic main features of study population.
MS (n = 32) OIND (n = 15) p
Sex, female: N (%) 24 (75) 7 (46.7) 0.056a
Age, years: mean (SD) 39.4 (11.6) 54.9 (14.5) 0.0002b
Age, years: median (min-max) 42.0 (19–60) 57.0 (28–78) –
Disease duration, months: mean (SD) 34.6 (67.2) – –
Number of MRI T2 lesions: mean (SD) 12.9 (10.0) – –
MRI Gd enhancement, yes: N (%) 16 (50.0) – –
CSF-restricted IgG OCB, positive: N (%) 24 (75.0) – –
aChi-square test.
bU-test.
CSF, cerebrospinal fluid; Gd, gadolium; MRI, magnetic resonance imaging; MS, multiple
sclerosis; OCB, oligoclonal bands; OIND, other inflammatory neurological diseases; SD,
standard deviation.
OIND: acute inflammatory demyelinating polyneuropathy (4 patients), MRI-negative
clinically isolated syndromes (3), chronic inflammatory demyelinating polyneuropathy (2),
other inflammatory disease of CNS (1), vascular ischemic disorder (1), isolated myelitis
(1), polineuropahy (1), isolated optic neuritis (1), systemic lupus erythematosus (1).
TABLE 2 | Percentage of cerebrospinal fluid samples with detectable levels of
MMPs.
MS; n(%) OIND; n(%)
MMP-1 31 (96.9) 15 (100)
MMP-2 32 (100) 15 (100)
MMP-3 1 (3.1) 0 (0)
MMP-7 32 (100) 15 (100)
MMP-8 30 (93.8) 14 (93.3)
MMP-9 20 (62.5) 5 (33.3)
MMP-10 31 (96.9) 15 (100)
MMP-12 31 (96.9) 15 (100)
MMP-13 11 (34.4) 3 (20)
MMPs, matrix metalloproteinases; MS, multiple sclerosis; OIND, other inflammatory
neurological diseases.
undetectable in almost all samples andMMP-13 was present only
in a small percentage of both MS patients and controls. MMP-3
and MMP-13 were therefore excluded from further analysis.
CSF MMP-1 and MMP-12 levels were significantly higher in
OIND than inMS patients after adjusting for sex and age at study
time (ANCOVA; p= 0.009 and p= 0.012, respectively) (Table 3).
No further statistically significant differences were found between
CSF MMPs concentrations comparing MS and OIND subjects.
MMP CSF Levels and Sex in MS and
Controls
MMP-1 CSF levels were significantly increased in female than
in male patients (MS + OIND) (Mann–Whitney; p = 0.0070,
Figure 1A). There was no significant difference in age between
female and male MS patients at the time of sample withdrawal
(40.4 vs. 36.6 years, respectively; p = 0.5277). CSF MMP-1 levels
were higher in female than in male MS patients (Mann-Whitney;
p = 0.0173) (Figure 1B). Moreover, an almost reached statistical
significance was found for CSF MMP-10 higher concentrations
in female than in male MS subjects (Mann–Whitney; p= 0.0567)
(Figure 1C). No further statistically significant difference was
detected for other MMP CSF concentrations by sex nor by status
(data not shown).
MMP CSF Levels and Age in MS and
Controls
CSF MMP-12 concentrations were positively correlated to age
in the overall sample (Spearman; r = 0.5155 and p = 0.0002)
while CSF MMP-7 levels and age correlation almost reached




MMP-1 70.8 (5.1) 67.0 (8.0) 0.009
(60.6, 81.0) (51.0, 83.0)
MMP-2 195.4 (20.4) 160.3 (32.1) 0.441
(154.2, 236.6) (95.6, 225.0)
MMP-7b 3.89 (0.15) 3.20 (0.24) 0.052
(3.58, 4.20) (2.71, 3.69)
MMP-8b 1.41 (0.14) 1.83 (0.21) 0.132
(1.14, 1.69) (1.39, 2.26)
MMP-9b 1.63 (0.27) 2.47 (0.65) 0.447
(1.06, 2.19) (1.13, 3.81)
MMP-10b 2.28 (0.08) 2.72 (0.13) 0.512
(2.11, 2.45) (2.47, 2.98)
MMP-12b 1.21 (0.13) 1.52 (0.20) 0.012
(0.95, 1.47) (1.11, 1.92)
MMPs, matrix metalloproteinases; MS, multiple sclerosis; OIND, other inflammatory
neurological diseases.
aAnalysis of covariance (ANCOVA) marginal means: MMPs as dependent variable, status
(MS vs. OND) as fixed factor, and sex and age at study time as covariates.
bAfter log-normal transformation of MMP concentration.
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FIGURE 1 | Matrix metalloproteinases (MMPs) cerebrospinal fluid (CSF) levels in patients affected by multiple sclerosis (MS) and by other inflammatory neurological
diseases (OIND) considered as a whole and classified according to clinical diagnosis and clinical features. MMP-1 levels were higher in female than in male patients
considered as a whole (Mann–Whitney; p = 0.0168, (A). MMP-1 levels were increased in female than in male MS patients (Mann–Whitney; p = 0.0173) (B). MMP-10
levels were more elevated in female than in male MS patients, however the p value did not reach the significance (Mann–Whitney; p = 0.0567) (C). MMP-7 and
MMP-12 concentrations were positively correlated to age in the overall sample (Spearman; r = 0.2920 and p = 0.0321, r = 0.5674 and p < 0.0001, respectively) and
in the OIND group (Spearman; r = 0.6924 and p = 0.0053, r = 0.6052 and p = 0.0187, respectively) (D,E). MMP-10 levels were higher in MS patients positive for the
presence of IgG oligoclonal bands (OCB+) than in negative (OCB-) (Mann–Whitney; p = 0.0173) (F). CSF total protein levels were positively correlated to age in MS
and OIND (Spearman; p = 0.0026 and p = 0.0042, respectively) (G). In CSF: MMP-7 and total protein concentrations were positively correlated in MS and OIND
(Spearman; p = 0.0112 and p < 0.0001, respectively) (H), while MMP-12 positively correlated to total protein in OIND (Spearman; p = 0.0199) (I). Each point
represents a single observation. Horizontal bars indicate medians (A–C,F).
statistical significance (Spearman; r = 0.2788 and p < 0.0577).
CSF MMP-7 and MMP-12 levels showed a positive correlation
to patients’ age (years) at study time only in the OIND group
(Spearman; r= 0.6924 and p= 0.0053, r= 0.6052 and p= 0.0187,
respectively) (Figures 1D,E). No other statistically significant
correlations were found between MMPs levels and age in MS and
OIND groups (data not shown).
MMP CSF Levels and Intrathecal IgG
Synthesis in MS Patients
Twenty-four (75%) MS patients were positive for CSF-restricted
IgG OCB (OCB+ MS). OCB+ MS and OCB negative MS
patients (OCB- MS) showed no differences in age at the time
of sample withdrawal (38.6 vs. 42.0 years; p = 0.4597). MMP-
10 CSF levels were higher in OCB+ than in OCB- MS patients
(Mann–Whitney; p = 0.0173) (Figure 1F), while no other
statistically significant differences were detected in other MMPs
CSF concentrations between the two MS subgroups (data not
shown).
MMP and Total Protein CSF Levels in MS
and Controls
CSF total protein levels were positively correlated to age in the
overall samples (Spearman; r = 0.6310 and p < 0.0001) and in
MS andOIND subgroups (Spearman; r= 0.5136 and p= 0.0026,
r = 0.7067 and p = 0.0042, respectively) (Figure 1G). MMP-7
and total protein CSF concentrations were positively correlated
in the overall samples (Spearman; r= 0.5303 and p= 0.0001) and
inMS andOIND patients (Spearman; r= 0.4424 and p= 0.0112,
r= 0.8821 and p< 0.0001, respectively) (Figure 1H). CSFMMP-
12 levels positively correlated to CSF total protein concentrations
in the overall samples (Spearman; r = 0.31353 and p = 0.0319)
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and in OIND subjects (Spearman; r = 0.6007 and p = 0.0199)
(Figure 1I). No further statistically significant correlations were
between MMPs levels and total CSF protein concentrations (data
not shown).
MMP CSF Levels and Disease Duration in
MS Patients
MS patients with long disease duration (defined as more than
12 months) were older than patients with short disease duration
(defined as 0–12 months) (48.5 vs. 38.6 years; p = 0.0009). The
analysis of covariance (ANCOVA) was used to compare CSF
MMPs levels in MS patients by dichotomised disease duration
and adjusting for age at study time (Table 4). CSF MMP-7
concentrations only were found to be statistically greater in MS
patients with long disease duration as compared to short disease
duration (p= 0.034).
MMP CSF Levels and Magnetic Resonance
Features in MS
Detectable CSF levels of any MMP under study did not differ in
MS patients with MRI evidence of disease activity vs. non active
MRI (data not shown). CSF MMPs levels were similar in Gd+
and in Gd- MS patients and were not associated with the number
of T2-weighted lesions (data not shown).
DISCUSSION
To the best of our knowledge, for the first time, we report
a reduced expression of MMP-1 and MMP-12 in the CSF of
patients with MS as compared to subjects with OIND, after
adjusting for sex and age at study time. A regulated MMP
activity contributes to physiological synaptic plasticity, while
dysregulated activity can produce tissue injury. Allen and coll.
demonstrated that the application of exogenous MMP-1, in
vitro, stimulated dendritic arborization, while overexpression of
MMP-1, in vivo, increased dendritic complexity and induced
biochemical and behavioral endpoints (18). These data suggest
an important role of MMP-1 in maintaining neuronal plasticity.
Conflicting results were previously reported on the role of
MMP-12 within the CNS. In fact, MMP-12 were associated
to both demyelination (19) and remyelination (20). Despite
of the detrimental role of almost all MMPs, some of them,
including MMP-1, have been associated to physiological and
neurogenesis processes comprisingmyelination and proliferation
and differentiation of neural progenitor cells (21, 22). In light of
this, the reduced expression of some MMPs in the CNS of MS
patients could reflect a minor capability in tissue repairing.
In our study MS population, MMP-7 CSF levels were found to
be directly associated with disease duration, even after adjusting
for age at study time. MMP-7 was found in association with a
protective and/or anti-inflammatory role in MS, and clearly in
the early phases of the disease as compared to neurodegeneration.
It was previously shown that MMP-7 was lower in children
with MS as compared to controls and that the treatment with
interferon-β was able to increase serum MMP-7 concentrations
(23).
We found that MMP-10 CSF levels were higher in OCB+
than in OCB- MS patients. Detection of CSF IgG OCB
remains both a fundamental support to the diagnosis and a
prognostic factor in MS (16). The significance of OCB in the
pathogenesis and/or prognosis of MS is still unclear, however
MS patients with no IgG OCB in their CSF are more likely
to show better prognosis (24). The production of IgG OCB
seems to be sustained by the presence of CNS infiltrating
plasma cells in MS lesions and to the presence of tertiary
lymphoid structures in the meningeal compartment (25). These
structures recapitulate lymphoid follicle-like features providing
an excellent microenvironment for the interaction of B and T
cells. MMP-10 was described as mainly expressed by monocytes
and by stimulated T-cells, however, a lower expression was also
demonstrated in both stimulated and unstimulated B-cells (9). In
this perspective, in OCB+ MS patients, CSF elevated MMP-10
concentrations could reflect a remarkable presence of resident T
and B cells as compared to OCB- MS subjects.
Surprisingly, in the present study we did not find any
correlation withMRImarkers of disease activity and progression.
This is in contrast with our previous evidences that the active
forms of MMP-2 and MMP-9 were correlated to MRI evidence
of disease remission or activity, respectively (12, 13). An
explanation of this apparently conflicting result might be ascribed
to different techniques used in the first two studies, in which only
the active enzyme forms and not the total amount of both MMP-
2 and MMP-9 were assessed. Of note, many MMPs are expressed
as inactive zymogens which require extracellular activation (26).
Gender-specific patterns are an interesting research focus
in MS due to the high and increasing women:men ratio
(27). Women generally have an earlier onset of disease,
counterbalanced by a less progression of disability than men
TABLE 4 | Adjusted mean (95%CI) levels of MMPs (pg/ml) and disease duration (months) among 32MS patientsa.
MMP-1 MMP-2 MMP-7b MMP-8b MMP-9b MMP-10b MMP-12b
Disease duration (months)
0–12 74.2 (60.9, 87.6) 208.3 (157.1, 259.5) 3.5 (3.1, 3.8) 1.6 (1.3, 1.8) 1.6 (1.0, 2.2) 2.4 (2.2, 2.6) 1.2 (1.0, 1.4)
>12 76.7 (57.4, 96.0) 180.1 (106.2, 253.9) 4.3 (3.8, 4.7) 1.5 (1.1, 1.8) 1.9 (0.7, 3.1) 2.3 (2.0, 2.5) 1.0 (0.7, 1.3)
p 0.647 0.744 0.034 0.295 0.136 0.095 0.075
MMPs, matrix metalloproteinases; MS, multiple sclerosis.
aANCOVA marginal means (95%CI) with MMPs as dependent variable, disease duration (12 vs. > 12 months) as fixed factor and age at study time as covariate.
bAfter log-normal transformation of MMP concentration.
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(28). In the overall study population, and in MS patients, CSF
levels of MMP-1 were higher among women than men. An effect
of gender on MMPs was reported in previous studies. MMP-9
serum levels were higher in female than in male population (29)
and MMP-2 mRNA was reported to be reduced in response to
the female hormone 17β-estradiol (30). Moreover, 17β-estradiol
decreased degradation of tight junction proteins and suppressed
the up-regulation ofMMPs expression leading a protective role of
estrogenin in BBB disruption using an in vitro and in vivomodel
(31). Our result is also in line with a previous study in which
MMP-3 levels were associated to male sex and to a low level of
MMP-1 (32).
In the overall sample we found an association between aging
and CSF MMP-12 levels, while in the OIND group both MMP-
7 and MMP-12 were positively associated to age. Previous study
showed that MMP-7 was associated with a reduction in N-
methyl-D-aspartate receptor stimulated calcium flux and authors
speculated on a protective role of this MMP in age-related
neurodegenerative diseases (33).Moreover, in the overall samples
MMP-7 and MMP-12 were positively correlated to CSF total
protein concentrations indicating a relationship between the
levels ofMMP-7 and the increased BBB permeability that occur in
aging (17). Increased MMP-12 were previously reported in mice
brain during aging, suggesting that the enzyme could enhance
the age-associated neuroinflammation (34). When patients were
grouped according to the diagnosis, the correlations between
MMPs and age were confirmed only in the control group
suggesting that the relationship between high levels of some
MMPs and patient’s age becomes more significant with aging.
The main limitations of this study were certainly the small
sample size of the OIND group and the lack of a control group
including non-inflammatory neurological diseases. However, the
differences detected for MMP-1 and MMP-12 suggest patterns
specifically associated to MS.
Taken together our results paint a novel and interesting
picture of the role of MMPs in MS, with regard to
other immunological features of CSF (e.g., OCB and
BBB permeability), but also disease duration. Sex-
specific differences were also detected in MMPs CSF
levels.
Future studies in largerMS populations and on serum samples
are however needed to explain (i) the detailed function and
interrelationship of MMP-1, MMP-7, MMP-10, and MMP-12 in
MS and (ii) the potential use of these molecules as biological
markers during neuroinflammation -degeneration and in tissue
repairing (35).
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